Check ER004 given in the womb for a genetic tooth-skin disorder
Part of Genetic & congenital, Skin clinical trials.
This Phase 2 study tests ER004 put into the amniotic fluid during pregnancy to treat male babies with X-linked hypohidrotic ectodermal dysplasia (XLHED). It also looks at effects in affected male relatives with the same gene change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Pregnancy must be confirmed, and you must be no later than 23 weeks 6 days pregnant
- The mother must be a confirmed carrier of an EDA gene mutation (genetic test confirms this)
- The baby must be diagnosed with XLHED and be male
- There must be no major extra body problem besides XLHED that could strongly affect safety or outcomes
- The family must include an untreated male relative (6 months to 75 years) with the same EDA mutation
- There must be no active serious pregnancy infection and no known maternal HIV infection
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called ECUR-506 for baby boys under 9 months old with a severe form of OTC deficiency. The goal is to see if it can help their bodies process ammonia better, reducing the need for a strict protein-restricted diet and medications.
This Phase 1 trial tests an enzyme replacement treatment given to a developing baby before birth for specific inherited “lysosomal storage” diseases. The goal is to see if the treatment is safe and can improve outcomes for babies diagnosed in pregnancy.
This Phase 3 study tests a medicine to help prevent abnormal calcium (called ectopic mineralization) from building up in people with pseudoxanthoma elasticum (PXE). It aims to slow or reduce new damage over time.
This study looks at the choices families have when they carry a genetic skin condition. It aims to learn more about how prenatal testing and IVF with genetic testing can help.
This trial is testing a new treatment called EXG110 for people with Fabry disease. It's designed to see if it's safe and if it can help. You may be able to join if you have a confirmed diagnosis and at least one symptom of Fabry disease.
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
Hear when a new X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.